November 8, 2015 11:21am
Despite recent troubles and increased volatility, investors still need to apply the brakes if necessary, lower the speed and do not stop until you have passed the short lines
Be especially careful never to overshoot your final turn or price. Subscription required, read more … http://www.regmedinvestors.com/user/register
Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.
U.S. stocks closed mixed Friday, but held solid gains for the week after a better-than-expected October jobs report increased confidence in the likelihood of a December rate hike.
The NASDAQ closed UP +19.38 or +0.38% to 5,147.12 and the DOW also closed UP +46.90 or +0.26% to 17,910.33.
Henry’omics:
Despite mixed performance Friday, the three major indexes rose nearly 1% or more for the week, their sixth-straight week of gains. That is the longest win streak for the major averages since late last year.
- However, markets are pricing in an approximately 70% probability of a rate hike in December, up from 58% before the report <CME's FedWatch tool>.
The stem, cell and gene therapy RegMed sector opened - negative at the open while traders sold <yet again> into any strength but, the Advance/Decline Line did notch to the upside at the mid-day <24/15> staying there at the 3 pm hour <25/16> to close in positive territory <27/14>.
- I also love quoting, that high-frequency trading accounted for 49% of November's daily trading volume of about 7.1 billion shares. During the peak levels of high-frequency trading in 2009, about 61% of 9.8 billion of average daily shares traded were executed by high-frequency traders. <TABB Group>
- These numbers# are telling investors – they are NOT in control!!
Thus, investors should be welcoming the advances after the downward moves of the week and today’s session as a sign of relief although, not a bottom forming!
- My fear gauge – The CBOE Volatility Index (VIX) fell below 15.
Earnings:
Most would agree the fundamental situation has not changed much, with exception of a handful of “so-so” received financial results/earnings reports, which is different than the previous quarter:
- Stemline (STML) reported <11/6> a Q3/15 net loss of -$9.2 M or -$0.53 per share with $28.5 M in cash, STML closed DOWN -$0.46 to $8.57;
- Osiris (OSIR) reported <11/6> a Q3/15 net loss of -$374 K or -$0.02 per share with $43.2 M in cash, OSIR closed DOWN -$3.71 to $14.54;
- Pluristem (PSTI) reported <11/6> a Q3/15 net loss of -$5.87 M or -$0.07 per share with $10.8 M in cash, PSTI closed DOWN -$0.02 to $1.71;
A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:
Volatility has been seemingly multi directional — meaning that the “our” universe’s low volume added to volatile spikes enhances sharp reversals.
- The SCGT & RM equities opened negative with an Advance/Decline line (A/DL) of 15/24 and 3 flats;
- The mid-day concluded positive with an A/DL of24/15 and 4 flats;
- The closing bell rang positive to end the session with an A/DL of 27/14 and 2 flats.
Dosing the sector – what a day for the 43 Patients:
- Open: NEGATIVE with 25 decliners, 15 advances and 3 flats;
- Mid-day (1 pm): POSITIVE with 15 decliners, 24 advancers and 4 flats;
- Closing bell: POSITIVE with 14 decliner, 27 advancers and 2 flats
Friday’s trading indications: 5 hits/ 2 miss
- Athersys (ATHX) closed DOWN – hit;
- Applied Genetic Technology (AGTC) closed DOWN – miss;
- bluebird bio (BLUE) closed UP – hit;
- Caladrius Biosciences (CLBS) closed UP – hit;
- Capricor (CAPR) closed UP – miss;
- Cellectis S.A. ADR (CLLS) closed UP – hit;
- Cytori (CYTX) closed down – hit;
Riding the indexes and ETFs roller-coaster:
- The iShares Biotechnology Stocks ETF (IBB) closed down on Friday -0.90 or -0.27% following Thursday’s decline of -6.49 or -1.92% after Wednesday’s -1.45 or -0.43% after Tuesday’s advance of +1.02 or +0.30% following Monday’s advance of +12.60 or +3.87%;
- The NASDAQ Biotechnology index (NBI) closed down on Friday -12.79 or -12.79 or -0.37% following Thursday’s decline of -65.57 or -1.86% post Wednesday‘s -12.23 or 0.35 % after Tuesday’s advance of +3.74 or +0.11% following Monday’s advance of +131.08 or +3.84%;
- The Russell 2000 (IWM) closed up +0.84 or 0.71% on Friday following Thursday’s advance of +0.09 or +0.08% post Wednesday’s decline of -0.06 or -0.05% after Tuesday’s advance of+0.61 or +0.52% following Monday’s +2.40 or +2.08%;
- The SPDR SD&P Biotech ETF (XBI) closed down on Friday -0.04 or -0.06% following Thursday’s decline of -1.23 or -1.71% post Wednesday’s advance of +0.40 or +0.56% after Tuesday +0.64 or +0.90% following Monday’s advance of +4.48 or +5.72%;
Who closed down – top 5:
- Osiris (OSIR) closed down -$3.71 to $14.54;
- Juno Therapeutics (JUNO) -$2.12 to $49.69;
- Spark Therapeutics (ONCE) -$1.75 to $56.07;
- Stemline (STML) -$0.46 to $8.57;
- Applied Genetics Technologies (AGTC) closed down -$0.17 to $13.02
Who was UP – top 5:
- Bluebird bio (BLUE) closed up +$3.28 to $73.64;
- Regenxbio (RGNX) +$2.64 to $20.56;
- Kite Pharma (KITE) +$2.13 to $73.77;
- Aduro Biotech (AFRO) +$1.38 to $28.46;
- Cellectis ADR (CLLS) closed up +$0.86 to $42.14;
Flat:
- Mesoblast ADR (USOTC: MBLTY) at $12.33;
- ReNeuron (RENE.L) at $3.75;
All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
